Background: The ASCO Survivorship Committee identified the need to better understand the current scope of cancer survivorship research in order to identify future research priorities. A committee workgroup recently completed a survey addressing this issue. Methods: A survey was conducted previously to assess engagement of ASCO members in survivorship care and research. Of 14,098 members contacted, 2,899 (20.6%) responded. Of this group, 679 self-identified as (co-)principal investigator of a survivorship-related study. A follow-up survey was subsequently sent to these members and to 838 individuals at NCI-designated Cancer Centers identified through other means as being engaged in cancer survivorship research. The survey asked respondents to describe study characteristics (e.g., design, participants, outcomes) for each IRB-approved cancer survivorship-related study for which they served as (co-)principal investigator. Results: 609 of 1517 recipients (46%) responded and reported on 714 studies. 65% of studies were observational (OBS) and 35% were interventional (INT). OBS studies mostly focused on lymphoid/hematopoietic (26%), breast (19%), and more than one (13%) cancer, while INT studies mostly focused on breast (34%), more than one (15%) and lymphoid/hematopoietic cancers (10%). Age at time of diagnosis/treatment was most commonly 40-64 years for OBS (26%) and INT (32%) studies and least commonly > 65 years for OBS studies (24%) and < 21 years for INT studies (11%). Time since diagnosis was most commonly < 2 and least commonly > 5 years for OBS (39%, 29%) and INT (48%, 15%) studies. The most common primary/secondary objectives were physical (32%), quality of life (27%) and health behavior (22%) outcomes for OBS studies and quality of life (34%), physical (31%) and health behavior (25%) outcomes for INT studies; the least common objective was patterns and quality of care for OBS (2%) and INT ( < 1%) studies. Conclusions: Findings identify key gaps in current research that should be prioritized for future study. These include the relative lack of research on several common cancers (e.g., colorectal, prostate, and lung), on long-term and older ( > 65) and younger ( < 21) survivors, and on survivorship care delivery and quality.